Today's

top partner

for CFD

Defying today’s market downturn, water treatment company Hawkins (NASDAQ: HWKN) saw its shares move higher on Monday after announcing it has acquired all the assets of rival water treatment chemicals and equipment company Amerochem.

As of 12:25 p.m. ET, Hawkins stock is up 5.6%.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

Hawkins swoops in

“Amerochem has built an incredible business over the past 30 plus years,” explained Hawkins CEO Patrick Hawkins, “and has great relationships with its customers, suppliers and employees” that Hawkins intends to maintain and expand.

What Hawkins didn’t say, however, is how much it paid for Amerochem’s assets. Nor did the company give investors much information with which to determine if this deal is a good or bad one for Hawkins. Hawkins’ press release noted that its “footprint” will expand with the acquisition of Amerochem’s market, which is primarily in North Carolina.

The company did not give any indication of the size of the market in terms of either revenue or profitability.

Is Hawkins stock a buy?

Investors, therefore, seem to be taking it on faith that Hawkins made a good deal here. That’s not entirely without basis. Hawkins noted that this is only its second acquisition in North Carolina, which suggests it’s being careful about what it buys, and how much it pays. But investors are still flying pretty blind here as regards specifics.

Still, were I considering an investment in Hawkins stock, I’d be cautious. The stock trades for more than 27 times earnings, but analysts who follow Hawkins don’t expect the company to grow earnings much faster than 7% annually over the next five years. Free cash flow at the company is strong at $80 million generated over the last 12 months, in line with reported earnings. And Hawkins’ debt load is modest, less than $120 million net of cash, on a $2.2 billion market capitalization.

All things considered, I’d call this a good business but an overpriced stock. Lacking more data on the Amerochem acquisition’s specifics, I see no reason to change this assessment.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $311,343!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,694!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $526,758!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 3, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the full story: Read More“>

Blog powered by G6

Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.

For any inquiries, please contact [email protected]